Saturday 17 October 2026
Export BNR’s income statement to Excel — free account
Burning Rock Biotech Limited Sponsored ADR
BNR Healthcare Diagnostics & Research
Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024. In the quarter to June 2026, revenue fell 4.22%, EPS fell 98.4%, free cash flow grew 46.0% and total debt fell 5.02%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
12.69
2.91
−18.65%
Follow BNR
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 4 | 6 | 5 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 25.58 | 7.23 | (1.61) | (4.58) | (5.70) | (2.95) |
P/S ratio |
0.00 | 0.00 | 0.00 | 381.27 | 12.46 | 2.75 | 1.31 | 0.98 | 2.78 |
Altman Z″-Score (non-manufacturers) |
— | (11.27) | — | 13.35 | 3.10 | (4.39) | (9.52) | (12.40) | (11.46) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | (1.54) | (4.17) | (4.34) | (2.87) | (2.47) |
P/Operating CF |
0.00 | 0.00 | 0.00 | (1,830.84) | (54.37) | (19.46) | (31.36) | 21.56 | 67.70 |
P/B ratio |
0.00 | 0.00 | 0.00 | 64.79 | 3.43 | 1.34 | 0.92 | 0.87 | 2.80 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 64.89 | 3.44 | 1.34 | 0.92 | 0.87 | 2.80 |
EV/Sales |
0.00 | 0.00 | 0.00 | 375.83 | 9.60 | 1.20 | 0.20 | 0.01 | 1.89 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | (8,207.08) | (10.21) | (1.47) | (0.42) | (0.04) | (35.81) |
EV/FCF |
0.00 | 0.00 | 0.00 | (8,207.08) | (10.21) | (1.47) | (0.17) | (0.02) | (8.83) |
Quick Ratio |
— | 0.75 | 3.78 | 9.83 | 4.29 | 2.52 | 2.82 | 2.53 | 2.63 |
Current Ratio |
— | 1.03 | 4.24 | 10.45 | 4.89 | 3.06 | 3.36 | 2.92 | 2.99 |
Net Debt/EBITDA |
0.00 | (0.99) | 2.48 | 5.92 | 1.94 | 1.02 | 1.15 | 1.71 | 14.48 |
Debt/Assets |
0.00% | 73.06% | 0.00% | 1.58% | 2.27% | 3.17% | 0.00% | 0.00% | 0.23% |
Debt/Equity |
— | (37.07) | 0.11 | 0.02 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 1.16 | 2.04 | 0.29 | 0.21 | 0.28 | 0.40 | 0.53 | 0.65 |
Operating CF/Net income |
0.72 | 0.64 | 0.68 | 0.16 | 0.60 | 0.47 | 0.39 | 0.27 | 0.51 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (2.37) | (4.46) | (0.55) | (0.07) | (0.08) | (0.20) |
Interest Coverage |
(24.51) | (19.43) | (155.72) | (619.66) | (519.00) | 9,476.33 | — | — | (1,961.00) |
| 0.00% | 32.53% | 44.80% | (59.51%) | (37.85%) | (61.56%) | (66.68%) | (50.57%) | (10.14%) | |
| 0.00% | (129.38%) | (178.19%) | (31.28%) | (32.66%) | (47.92%) | (48.89%) | (35.47%) | (6.64%) | |
ROIC |
— | 0.00% | 0.00% | (146.67%) | (126.40%) | (216.16%) | (273.06%) | (380.90%) | (61.14%) |
Return on Tangible Assets |
0.00% | (309.58%) | (54.16%) | (19.72%) | (44.91%) | (88.36%) | (86.85%) | (62.18%) | (10.59%) |
Average Days of Receivables |
0.00 | 138.87 | 197.84 | 74.90 | 66.26 | 71.26 | 86.16 | 107.57 | 114.74 |
Research and Development Expense of Revenue |
44.10% | 50.41% | 41.12% | 61.40% | 72.43% | 74.90% | 64.57% | 45.03% | 30.86% |
Selling, General and Administrative Expense of Revenue |
129.12% | 91.52% | 74.80% | 107.56% | 156.22% | 166.64% | 127.56% | 87.73% | 53.98% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 40.29% | 55.61% | 58.02% | 48.51% | 30.17% | 2.57% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.01 | 0.22 | 0.54 | 0.87 | 0.93 | 0.30 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(1.18%) | (1.18%) | (1.18%) | (1.99%) | (12.38%) | (63.89%) | (91.85%) | (21.18%) | (2.48%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | (0.01%) | (7.55%) | (29.51%) | (87.69%) | (44.36%) | (7.71%) |
Revenue per Share |
0.16 | 0.30 | 0.53 | 9.60 | 7.65 | 7.86 | 7.39 | 6.87 | 7.26 |
Operating CF per Share |
(0.19) | (0.22) | (0.32) | (1.64) | (7.20) | (6.37) | (3.52) | (1.23) | (0.38) |
Capex per Share |
0.00 | 0.00 | 0.00 | (1.76) | (3.21) | (0.95) | (0.13) | (0.06) | (0.06) |
Free Cash Flow per Share |
(0.19) | (0.22) | (0.32) | (3.40) | (10.40) | (7.32) | (3.65) | (1.29) | (0.44) |
Cash per Share |
0.00 | 0.19 | 0.57 | 51.07 | 22.63 | 12.91 | 8.46 | 6.95 | 6.47 |
Shareholders Equity per Share |
0.00 | (0.01) | 0.88 | 54.06 | 27.79 | 16.16 | 10.57 | 7.73 | 7.20 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | (0.01) | 0.88 | 54.06 | 27.79 | 16.16 | 10.57 | 7.73 | 7.20 |
Free Cash Flow |
(19.78) | (22.48) | (33.00) | (23.36) | (108.40) | (76.10) | (37.33) | (13.24) | (4.70) |
Working Capital |
— | 1.21 | 76.47 | 349.75 | 227.34 | 122.85 | 87.43 | 69.91 | 70.30 |
Capital Expenditures |
(3.41) | (3.74) | (6.62) | (12.09) | (33.40) | (9.87) | (1.31) | (0.60) | (0.63) |
Net Current Asset Value |
— | (12.39) | 69.78 | 349.68 | 217.76 | 120.29 | 86.27 | 64.68 | 64.85 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.18 | 0.42 | 0.12 | 0.02 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.00 | 0.37 | 0.35 | 0.30 | 0.15 | 0.49 | 1.01 | 1.11 | 0.70 |
Cash ROIC |
0.00% | (38.88%) | (20.61%) | (3.21%) | (20.32%) | (24.60%) | (19.16%) | (8.76%) | (3.23%) |
Accounts Receivable Turnover |
0.00 | 1.50 | 2.63 | 3.03 | 5.69 | 5.37 | 4.48 | 3.65 | 3.42 |
Accounts Payable Turnover |
2.75 | 5.25 | 7.57 | 4.93 | 2.94 | 3.07 | 4.94 | 5.87 | 3.74 |
Inventory Turnover |
1.65 | 3.15 | 2.02 | 1.89 | 1.52 | 1.39 | 1.71 | 2.30 | 2.52 |
Average Days of Payables |
117.46 | 77.53 | 41.27 | 111.67 | 160.21 | 101.51 | 37.84 | 80.28 | 108.82 |
Days of Inventory on Hand |
(4.52) | 233.80 | 194.22 | 214.07 | 312.92 | 259.65 | 144.60 | 148.99 | 129.74 |
Average Receivables |
— | 20.97 | 20.97 | 21.73 | 13.99 | 15.21 | 16.91 | 19.35 | 22.54 |
Average Payables |
2.12 | 2.12 | 2.07 | 3.61 | 7.67 | 8.64 | 4.97 | 3.58 | 5.22 |
Average Inventory |
3.54 | 3.54 | 7.74 | 9.38 | 14.88 | 19.12 | 14.31 | 9.15 | 7.76 |
Average Assets |
— | 27.14 | 27.14 | 231.20 | 382.85 | 293.86 | 188.32 | 133.89 | 119.30 |
Average Common Equity |
— | (107.94) | (107.94) | 121.53 | 330.30 | 228.76 | 138.09 | 93.90 | 78.06 |
Columns are period end dates